ZAI Laboratory
Building B, 899 Halei Road, Pudong, Shanghai, 201203, China
Overview
Zai Lab is an innovative biopharmaceutical company based in Shanghai focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. Since their founding in 2014, their experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates. They see theirselves as the trusted partner of choice for global biopharmaceutical companies seeking to access the Chinese market. Leveraging their team’s extensive global drug development expertise, combined with their demonstrated understanding of the pharmaceutical industry, the increasingly favorable clinical and regulatory environment in China and their in-house manufacturing capabilities, they plan to continue to secure relationships with global pharmaceutical companies to further expand their pipeline and foster innovation in China. Their team is passionate about bringing transformative new medicines to patients. Their vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing their partner’s and their own products in China and around the world. To that end, they have built manufacturing capabilities to support the clinical and commercial production of their drug candidates in China, and they expect to have further clinical production capabilities in the near future. Their team is planning to establish a specialized commercial team to support marketing of their products in China and beyond, and they are expanding their discovery efforts both internally and through collaborations with leading academic institutions.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Biotechnology
- Health Care
- Pharmaceutical
Investment portfolio
- dMed
Participated · Series A · Dec 2016
dMed-Clinipace is a merged global full-service CRO formed by the combination of dMed Global and Clinipace Incorporated. The company provides clinical development, regulatory, pharmacovigilance and clinical analytics services with therapeutic focus in oncology, rare disease, gastroenterology, nephrology and women’s health. Led by Global Chairman and CEO Dr. Lingshi Tan, the CRO supports end-to-end clinical programs. The Series C+ financing proceeds helped finance the merger announced in April 2021. The organization employs more than 1,700 staff across 22 offices in the Americas, Europe and Asia-Pacific, including over 700 staff in China. Investors from prior angel, A and B rounds have continued to increase their contributions since dMed’s inception in 2016. dMed is a full-service clinical CRO that provides consulting, regulatory affairs and strategy, early clinical development, clinical science and medical affairs, clinical operations, biostatistics and programming, data management, drug safety and pharmacovigilance, quality assurance and information solutions. The company leverages and integrates China’s new regulatory framework to offer innovative drug development strategies and help clients expand globally into the world’s second-largest pharmaceutical market. dMed says its collaboration models aim to raise efficiency in clinical R&D, shorten research cycles, and boost success rates for innovative pharma companies. It has established offices in major cities including Shanghai, Beijing, Wuhan, New York, Washington, San Francisco, and Brussels. The company is led by Founder, Chairman and CEO Dr. Lingshi Tan and employs around 600 professionals globally. The business targets both Chinese and international pharmaceutical and medical device clients seeking to run clinical programs in China and worldwide. dMed is a global “next generation” full-service clinical CRO providing end-to-end industry solutions for pharmaceutical and medical device companies. Its offerings span consulting, early development and clinical pharmacology, clinical operations, biostatistics and programming, data management, safety and pharmacovigilance, clinical science, quality assurance, and regulatory affairs and strategy. The company has offices in major cities including Shanghai, Beijing, Wuhan, New York, Washington, San Francisco, and Brussels, and employs more than 600 professionals globally. dMed completed the acquisition of Target Health, a New York-based CRO, mid-year to extend its global footprint and add technologies to its services. The company plans to use the new funding to accelerate expansion of its clinical operations and information technology infrastructure, and to extend global capacity in clinical development and product registration. Led by founder and CEO Dr. Lingshi Tan, dMed has attracted industry elites and experts in China and the US since its launch three years ago. dMed is a China-based contract research organization that provides comprehensive services to biopharmaceutical and medical device companies in China and globally. Its offerings include advising customers on clinical development plans, regulatory strategy, approval processes, and full clinical trial support. The company was founded in 2016 by Lingshi Tan. dMed raised $8M in a Series A round to support growth. It intends to use the funds to expand its assurance and clinical operations teams. Founder Lingshi Tan previously served as Pfizer’s Vice President of Worldwide Development Operations and Chairman and General Manager of Pfizer (China) R&D.
Team
No current team members are available.